

WFNOS – World Federation of Neuro-Oncology Societies



SCIENTIFIC LUNCHTIME SYMPOSIUM
FRIDAY, 5TH MAY 2017, 12.35–14.00h

Glioblastoma therapy with Tumor-Treating Fields (Optune®)

Kongressaal (main auditorium)

GLIOBLASTOMA THERAPY WITH TUMOR-TREATING FIELDS (OPTUNE)

Speakers



Chair Prof. Dr. Michael Weller
Chairman, Clinic for Neurology, University Hospital Zurich, Switzerland



Co-Chair Maciej M. Mrugala, MD, Ph.D.
Senior Associate Consultant, Neuro-Oncology, Mayo Clinic Phoenix AZ, USA



Patrick Roth, MD
Senior leading physician, Department of Neurology, University Hospital Zurich, Switzerland



David A. Reardon, MD
Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston MA, USA



Prof. Dr. Martin Glas
Head Division of Clinical Neuro-Oncology, Dept. of Neurology, University of Essen Med Ctr, Germany



Dr. Giovanni Luca Ceresoli
Head of Thoracic and Urological Oncology Unit, Department of Medical Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy

Program

12.35 - 12.40 h

Welcome and Introduction
(M. Weller, M. Mrugala)

12.40 – 12.55 h

Biological effects of TTFields in glioblastoma
(P. Roth)

12.55 - 13.15 h

The EF-14 newly diagnosed GBM study in the context of clinical trials: an overview about the current situation in Glioblastoma treatment
(A. Reardon)

13.15 - 13.35 h

Optune in daily clinical practice, chances and challenges
a) US perspective (M. Mrugala)
b) European perspective (M. Glas)

13.35 - 13.50 h

Outlook: TTFields in other indications
(GL. Ceresoli)

13.50 - 14.00 h

Q&A Session/Closing remarks/Take away messages
(M. Weller)

INVITATION

We are delighted to invite you to our **Scientific Lunchtime Symposium**
»Glioblastoma therapy with Tumor-Treating Fields (Optune)«
on **Friday, 5th May 2017**.


Renowned physicians will speak about the EF-14 study for newly diagnosed GBM as well as Optune in clinical practice and give an outlook about TTFIELDS biological effects and clinical testing in other indications.

Please join us for this interactive discussion on how the Optune therapy can benefit your patients.

Yours Sincerely,



Dr. Thomas Hefti
VP EMEA



Dr. med. Adrian Kinzel
Medical Director EMEA

**Visit us at our booth
to learn more about
Optune therapy.**



 **OPTUNE**[®]

therapy for newly diagnosed Glioblastoma (GBM)

 learn more at optune.com

© 2017 Novocure. All rights reserved. Optune and Novocure are trademarks of Novocure.
EU-SM-OPT-071-EN/ 1.0 / 04.2017

novocure[™]